After Mizuho Securities and Cantor Fitzgerald gave Aerie Pharma (NASDAQ: AERI) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst Esther Rajavelu maintained a Buy rating on Aerie Pharma today. The company’s shares opened today at $47.04.
According to TipRanks.com, Rajavelu is a 2-star analyst with an average return of 1.2% and a 54.2% success rate. Rajavelu covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Rocket Pharmaceuticals Inc, and Jazz Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aerie Pharma with a $80 average price target, a 70.1% upside from current levels. In a report issued on March 4, Canaccord Genuity also maintained a Buy rating on the stock with a $73 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $74.75 and a one-year low of $32.18. Currently, Aerie Pharma has an average volume of 688K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105.
